SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
dehydrogenase, glyceraldehyde phosphate (nicotinamide adenine dinucleotide phosphate) (phosphorylating) GAPDH glyceraldehyde phosphate dehydrogenase (nicotinamide adenine dinucleotide phosphate) (phosphorylating) glyceraldehyde-3-phosphate dehydrogenase (NADP) (phosphorylating) NADP-dependent glyceraldehyde phosphate dehydrogenase NADP-glyceraldehyde phosphate dehydrogenase NADP-glyceraldehyde-3-phosphate dehydrogenase NADP-triose phosphate dehydrogenase triosephosphate dehydrogenase (NADP)
An aponeurosis (; pl.: aponeuroses) is a flattened tendon by which muscle attaches to bone or fascia. Aponeuroses exhibit an ordered arrangement of collagen fibres, thus attaining high tensile strength in a particular direction while being vulnerable to tensional or shear forces in other directions. They have a shiny, whitish-silvery color, are histologically similar to tendons, and are very sparingly supplied with blood vessels and nerves. When dissected, aponeuroses are papery and peel off by sections. The primary regions with thick aponeuroses are in the ventral abdominal region, the dorsal lumbar region, the ventriculus in birds, and the palmar (palms) and plantar (soles) regions.
=== Other applications: blocking other mRNA sites and use as probes === Morpholinos have been used to block miRNA activity and maturation. Fluorescein-tagged Morpholinos combined with fluorescein-specific antibodies can be used as probes for in-situ hybridization to miRNAs. Morpholinos can block ribozyme activity. U2 and U12 snRNP functions have been inhibited by Morpholinos. Morpholinos targeted to "slippery" mRNA sequences within protein coding regions can induce translational frameshifts. Morpholinos can block RNA editing, poly(A) tailing and translocation sequences. Morpholino activities against this variety of targets suggest that Morpholinos can be used as a general-purpose tool for blocking interactions of proteins or nucleic acids with mRNA.
As the urban area continued to expand, much of rural Scarborough was converted to suburban housing developments in the last third of the 20th century. At the start of the 21st century, growth occurred along the Highway 401 corridor at the northern end of the Scarborough RT; highrise condominium projects have increased the residential density around Scarborough City Centre. In 1988, there was a reorganization. The board of control was abolished. Alderman was changed to councillor. Six additional metro council positions were created and these were elected separately for the first time. Scarborough's council consisted of a mayor, 14 local councillors and six Metro councillors. In 1998, the municipality of Scarborough was dissolved and the district amalgamated with East York, Etobicoke, North York, York, and the old city of Toronto into the current city of Toronto.
In 1848 the new Hanoverian law also provided for presbyteries in these Calvinist parishes, which exactly fit the presbyterian structure of Calvinism. Catholics formed an overall minority in Hanover, but regionally majorities in the former prince-bishoprics. By the annexations in 1803 and 1814, Hanover had become a state of three Christian denominations. In 1824, Hanover and the Holy See thus agreed to integrate diaspora parishes which were located in predominantly Protestant areas, until then supervised by the Roman Catholic Vicariate Apostolic of the Nordic Missions, into the existing dioceses of the former prince-bishoprics, whose diocesan territories were thus extended into the diaspora areas. Jews lived all over Hanover in diaspora. Until 1806, they were not allowed to reside in some areas. By the Westphalian and French annexations in 1807 and 1810, all-male inhabitants in later restituted Hanover became Westphalian or French citizens of equal rights. On 17 March 1808, Napoléon Bonaparte restricted the rights of Jews in the French-annexed territory by his so-called décret infâme. The Jewish congregations became subject to French regional Jewish consistories or the Royal Westphalian Consistory of the Israelites, respectively. In 1813, when Hanover resumed independence and sovereignty, its government deprived the Jews of their legal equality.
Sources: en.wikipedia.org
=== Exogenous sources === The formation of ROS can be stimulated by a variety of agents such as pollutants, heavy metals, allergens, cigarette smoke, drugs, insecticides, ozone, pesticides, toxins, UV radiation. In plants, in addition to the action of dry abiotic factors, high temperature, interaction with other living beings can influence the production of ROS. In a process termed radiolysis, through the interaction of water and ionizing radiation, damaging intermediates can be generated. In the process, a water molecule gets excited and subsequently dissociates into a hydrogen (•H) and a hydroxyl radical (•OH), which both are highly reactive. The radicals may attack cells and molecules on the cell surface, and through a chain reaction dozens of molecules can be damaged by the homolysis of a single water molecule. In plants, the production of ROS occurs during events of abiotic stress that lead to a reduction or interruption of metabolic activity. For example, the increase in temperature, drought are factors that limit the availability of CO2 due to stomatal closure, increasing the production of ROS, such as O2·- and 1O2 in chloroplasts. The production of 1O2 in chloroplasts can cause reprogramming of the expression of nucleus genes leading to chlorosis and programmed cell death. In cases of biotic stress, the generation of ROS occurs quickly and weakly initially and then becomes more solid and lasting. The first phase of ROS accumulation is associated with plant infection and is probably independent of the synthesis of new ROS-generating enzymes.
Historically, snuff spoons were used for cocaine in the 20th century, hence the names "cocaine spoon" and "coke spoon". Some local statutes in the US treat spoons that are too small and thus "unsuited for the typical, lawful uses of a spoon" as drug paraphernalia.
RNA editing (also RNA modification) is a molecular process through which some cells can make discrete changes to specific nucleotide sequences within an RNA molecule after it has been generated by RNA polymerase. It occurs in all living organisms and is one of the most evolutionarily conserved properties of RNAs. RNA editing may include the insertion, deletion, and base substitution of nucleotides within the RNA molecule. RNA editing is relatively rare, with common forms of RNA processing (e.g. splicing, 5'-capping, and 3'-polyadenylation) not usually considered as editing. It can affect the activity, localization as well as stability of RNAs, and has been linked with human diseases. RNA editing has been observed in some tRNA, rRNA, mRNA, or miRNA molecules of eukaryotes and their viruses, archaea, and prokaryotes. RNA editing occurs in the cell nucleus, as well as within mitochondria and plastids. In vertebrates, editing is rare and usually consists of a small number of changes to the sequence of the affected molecules. In other organisms, such as squids, extensive editing (pan-editing) can occur; in some cases the majority of nucleotides in an mRNA sequence may result from editing. More than 160 types of RNA modifications have been described so far. The discovery of RNA modifications that result in the suppressing of immunogenicity of therapeutic mRNA led to their eventual adoption for COVID mRNA vaccines, and was recognized with the 2023 Nobel Prize in Physiology or Medicine to Katalin Karikó and Drew Weissman.
On January 18, 2015, Alice in Chains performed in the halftime show of the NFC Championship Game between the Seattle Seahawks and the Green Bay Packers at CenturyLink Field in Seattle. Cantrell is a lifelong Seahawks fan and often attends their games. In August 2015, Bassist Mike Inez said that the band had been "throwing around riffs for a new record" and "taking it nice and slow". The band toured in the summer of 2015 and the summer of 2016, including select shows opening for Guns N' Roses as part of the Not in This Lifetime... Tour. The band finished their 2016 tour with a concert at the Grand Sierra Resort and Casino in Reno, Nevada on October 8, 2016. In November 2016, Alice in Chains released a cover of the Rush song "Tears", which was included in the 40th anniversary release of the album 2112. The home video Live Facelift was released on vinyl for the first time on November 25, 2016, as part of Record Store Day's Black Friday event. The album features six songs and only 5000 copies were issued. To celebrate the tenth anniversary of Record Store Day, on April 22, 2017, Legacy Recordings released "Get Born Again"/"What the Hell Have I", a special 45 RPM double 7" single featuring four tracks remastered and available on vinyl for the first time, "What the Hell Have I", "A Little Bitter", "Get Born Again" and "Died".
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.